www.innocyto.com

InnoCyto Inc.

15375 Barranca Pkwy, Suite I-103
Irvine, CA 92618
Email: info@innocyto.com
Phone: 1-949-418-7543

iF647 Anti-Mouse/Human integrin β7 Antibody

Catalog Number:	208103, 208104
Size:	25 µg, 100 µg
Target Name:	Integrin β7, β7 Integrin, integrin βp, ITGB7
Regulatory Status:	RUO

PRODUCT DETAILS

Clone:	FIB27
Application:	Flow Cytometry
Reactivity:	Mouse, Human
Format:	iF647
Isotype:	Rat IgG2a
Antibody Type:	Monoclonal
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA
Protein Concentration:	0.2 mg/mL
Storage & Handling:	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Recommended Usage:	For flow cytometric staining, it is recommended to use less than 0.2 µg of this reagent per 0.5-1.0 million cells in a 100 µL volume. Optimal reagent performance should be determined by titration for each specific application. iF647 has an excitation max at 656 nm and an emission max at 670 nm.
Excitation Laser:	Red Laser (633 nm)
Isotype Control:	303512

BACKGROUND INFORMATION

Human and mouse integrin β7 (ITGB7) is a leukocyte adhesion receptor subunit that regulates immune-cell trafficking, adhesion, and retention, particularly at mucosal surfaces. β7 does not function alone but forms heterodimers with two α subunits: α4β7 and αEβ7 (CD103). α4β7 is expressed prominently on gut-homing lymphocytes and mediates their migration from the circulation into intestinal tissues, whereas αEβ7 contributes to retention of lymphocytes within epithelial compartments. :contentReference[oaicite:0]{index=0}

β7 is a type I transmembrane integrin protein containing a large extracellular domain, a single transmembrane helix, and a short cytoplasmic tail involved in intracellular signaling. Like other integrins, β7-containing heterodimers undergo conformational changes that regulate ligand affinity and transmit bidirectional signals between the extracellular environment and the cytoskeleton. The principal ligand for α4β7 is mucosal addressin cell adhesion molecule-1 (MAdCAM-1), which is highly expressed on endothelial cells in intestinal tissues. α4β7 can also interact with VCAM-1 under certain conditions. The principal ligand for αEβ7 is E-cadherin on

epithelial cells. :contentReference[oaicite:1]{index=1}

β7-mediated trafficking and retention are physiologically important for intestinal immune surveillance but can contribute to chronic inflammation. Increased α4β7–MAdCAM-1 interactions promote recruitment of inflammatory lymphocytes into the intestinal mucosa in Crohn's disease and ulcerative colitis. αEβ7–E-cadherin interactions can additionally promote retention of activated lymphocytes within intestinal epithelium. β7-positive immune cells and their ligands have also been implicated in other inflammatory disorders, although evidence varies among diseases. :contentReference[oaicite:2]{index=2}

Because β7 controls mucosal immune-cell trafficking, it is an important therapeutic target. Vedolizumab selectively targets α4β7 and blocks its interaction with MAdCAM-1, providing gut-selective immunomodulation and established treatment for inflammatory bowel disease. Anti-β7 approaches such as etrolizumab target both α4β7 and αEβ7, potentially inhibiting both lymphocyte recruitment and epithelial retention. Thus, β7 represents an attractive target for developing therapies for inflammatory and autoimmune diseases involving pathological mucosal immune-cell trafficking. :contentReference[oaicite:3]{index=3}

PRODUCT DATA



Human peripheral blood lymphocytes were stained with PB Anti-Human CD3 clone 003CB and iF647 Anti-Mouse/Human integrin β7 clone FIB27 (left) or an isotype control (right).